Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Status:
Completed
Trial end date:
2006-03-13
Target enrollment:
Participant gender:
Summary
A study for patients diagnosed with advanced cutaneous T-cell lymphoma (stage 1B or higher)
who have progressive, persistent, or recurrent disease on or following 2 other therapies, one
of which must have contained Targretin (bexarotene)or for patients who are not candidates or
could not tolerate Targretin therapy.